i see alot of justification going to paris just because you can, but i can't, so i won't. Instead, i'll go to Jack-In-The-Box, and like it.
The MACK drugs are far from the market, clinical events are well off into 2014, but hype persists - and in this market - a spark of hype related to a biotech is all you need. Don't fight the tape - just enjoy the ride - merited or not - if you happen to own.
i agree - Boogins also claims to have been a shareholder for "years" even though MACK's IPO was less than 2 years ago. He is knowledgeable but in a dangerous way that seems similar to "daviscupper" from the Celsion board who lured people in with his seemingly intelligent pumping of the stock.
I think that MACK has alot more going for it than CLSN but investors shouldn't get too enamored of one particular poster - and yet that seems to have happened with the flock that follows Boogins's every post.
I think MM-121 will show statistically significant positive results in at least one of the ongoing ph II BC studies but could potentially underwhelm in terms of PFS compared to Afinitor. That is, if MM-121 shows PFS of less than the 11 months demonstrated by Afinitor in a second line setting, will this be viewed positively or underwhelm the market? I think MM-398 will be positive in pancreatic cancer, but a better buy point may be coming when the BC results start to emerge. What do others think?
i believe you own 300K shares - that's less than 750K dollars, so not unheard of. i've actually owned more of a biotech (i owned 1.7 million dollars of inhibitex when it got taken out).
Go buy CLSN - you were quite the pied piper with that one. And of course you lied about owning, or not owning that one, as you are here - so give it all a rest.
KY - just remember that, and apply it liberally every morning before the market opens. That'll make the pain much less in the months ahead as this tanks.
C'mon - i'm not "always right", just frequently so, like today. You are bleeding, right? Well underwater on this one, aren't you. As i said, there's no honor in going down with the ship - sell.
i was an owner at one time - but now i'm sitting on the sidelines and taking a public service role by sharing my very valuable insights with you and others. Heed my warning - sell now and save yourself from essentially certain financial ruin.
Now you know - i speak the truth. You can still bail out of MEIP before it sinks below 7. There is neither honor nor dignity in going down with the ship. Save yourself the grief, and your finances the added losses, and sell now.
And right as rain. You known this story better than I - dilution, no news forthcoming for months, resulting disinterest given other more compelling biotechs out there, and the stock drifts downward
Stifel raised their price target on MEIP to $15 per share following the release of the ME-344 results. Of course, it turns out that Stifel, with Cowen, is a joint book running manager for MEIP's new secondary offering. Of course they would raise their price target - to keep this business coming their way. What Stifel really means is: don't pay attention to our price target.
Gold's pay, including bonus, is about $800K per year, and he has been granted millions in restricted stock, so he has minimal incentive to see the stock price rise. Some incentive but not nearly as much as if his pay were highly leveraged to options. Today's dilution at 8 per share is just the start. This is a dead stock for the foreseeable future.
Be careful - i just reviewed their SEC regulatory filings - including the new one that just came out - and the CEO, Gold, is paid largely in salary and restricted stock which is highly lucrative in his case even if the stock doesn't go up. His stock option grants are not nearly as significant. So - the CEO does well even if the stock doesn't go up much.
Was today's downturn related to the public offering of common stock announced after the close? It's going down yet again after hours. I fear that MEIP will end up being a serial dilution company like so many other biotechs.